Preventing and managing pelvic inflammatory disease: Key questions, practices, and evidence

Journal of Family Practice

Volumn 43, Issue 3, 1996, Pages 283-293

  Washington, Eugene ^a   Berg, Alfred O ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

diagnosis; Pelvic inflammatory disease; primary prevention; risk factors; treatment

Indexed keywords

ANTIBIOTIC AGENT; CEFOTETAN; CEFOXITIN; CEFTRIAXONE; CLINDAMYCIN; DOXYCYCLINE; GENTAMICIN; METRONIDAZOLE; OFLOXACIN; PROBENECID; SULTAMICILLIN;

ANTIBIOTIC THERAPY; CLINICAL FEATURE; CLINICAL PROTOCOL; DRUG CHOICE; DRUG COST; HUMAN; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PELVIC INFLAMMATORY DISEASE; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE;

AMBULATORY CARE; ANTI-INFECTIVE AGENTS; FEMALE; HOSPITALIZATION; HUMANS; PELVIC INFLAMMATORY DISEASE; RISK FACTORS;

EID: 0029844270     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. McCormack WM. Pelvic inflammatory disease. N Engl J Med 1994; 330:115-9.
2. Quan M. Pelvic inflammatory disease: diagnosis and management. J Am Board Fam Pract 1994; 7:110-23.
3. Rolfs RT, Galaid EI, Zaidi AA. Pelvic inflammatory disease: trends in hospitalizations and office visits, 1979 through 1988. Am J Obstet Gynecol 1992; 166:983-90.
4. Washington AE, Katz P. Cost of and payment source for pelvic inflammatory disease. Trends and projections, 1983 through 2000. JAMA 1991; 266:2565-9.
5. Marchbanks PA, Annegers JF, Coulam CB, Strathy JH, Kurland LT. Risk factors for ectopic pregnancy. A population-based study. JAMA 1988; 259:1823-64.
6. Weström L, Mårdh P-A. Acute pelvic inflammatory disease (PID). In: Holmes KK, Mårdh P-A, Sparling PF, Weisner PJ, eds. Sexually transmitted diseases. 2nd ed. New York, NY: McGraw-Hill Inc, 1990:593-613.
7. Washington AE, Cates W Jr, Wasserheit JN. Preventing pelvic inflammatory disease. JAMA 1991; 266:2574-80.
8. Rice PA, Schachter J. Pathogenesis of pelvic inflammatory disease. What are the questions? JAMA 1991; 266:2587-93.
9. Kahn JG, Walker CK, Washington AE, Landers DV, Sweet RL. Diagnosing pelvic inflammatory disease. A comprehensive analysis and considerations for developing a new model. JAMA 1991; 266:2594-604.
10. Walker CK, Kahn JG, Washington AE, Peterson HB, Sweet RL. Pelvic inflammatory disease: metaanalysis of antimicrobial regimen efficacy. J Infect Dis 1993; 168:969-78.
11. Centers for Disease Control and Prevention. 1993 Sexually transmitted diseases treatment guidelines. MMWR 1993; 42(RR-14):1-102.
12. Washington AE, Aral SO, Wølner-Hanssen P, Grimes DA, Holmes KK. Assessing risk for pelvic inflammatory disease and its sequelae. JAMA 1991; 266:2581-6.
13. Zorlu CG, Aral K, Cobanoglu O, Gurler S, Gokmen O. Pelvic inflammatory disease and intrauterine devices: prophylactic antibiotics to reduce febrile complications. Adv Contraception 1993; 9:299-302.
14. Washington AE, Gove S, Schachter J, Sweet RL. Oral contraceptives, Chlamydia trachomatis infection, and pelvic inflammatory disease. A word of caution about protection. JAMA 1985; 253:2246-50.
15. Cramer DW, Goldman MB, Schiff I, et al. The relationship of tubal infertility to barrier method and oral contraceptive use. JAMA 1987; 257:2446-50.
16. Wølner-Hanssen P, Eschenbach DA, Paavonen J, et al. Association between vaginal douching and acute pelvic inflammatory disease. JAMA 1990; 263:1936-41.
17. Jossens MOR, Schachter J, Sweet RL. Risk factors associated with pelvic inflammatory disease of differing microbial etiologies. Obstet Gynecol 1994; 83:989-97.
18. Sweet RL. Changing etiology of PID. In: Genitourinary infections in women: update on urinary tract infections and pelvic inflammatory disease. Consensus Conference Proceedings 1994. Sponsored by the University of Wisconsin Medical School. Little Falls, NJ: Health Learning Systems Inc, 1994.
19. Sellors J, Mahony J, Goldsmith C, Rath D, Mander R, Hunter B, et al. The accuracy of clinical findings and laparoscopy in pelvic inflammatory disease. Am J Obstet Gynecol 1991; 164:113-20.
20. Adelman A. Abdominal pain in the primary care setting. J Fam Pract 1987; 25:27-32.
21. Bongard F, Landers DV, Lewis F. Differential diagnosis of appendicitis and pelvic inflammatory disease. A prospective analysis. Am J Surg 1985; 150:90-6.
22. Patton DL, Moore DE, Spadoni LR, Soules MR, Halbert SA, Wang S-P. A comparison of the fallopian tubes response to overt and silent salpingitis. Obstet Gynecol 1989; 73:622-30.
23. Wølner-Hanssen P. Silent pelvic inflammatory disease: is it overstated? Obstet Gynecol 1995; 86:321-5.
24. Soper DE, Brockwell NJ, Dalton HP. Microbial etiology of urban emergency department acute salpingitis: treatment with ofloxacin. J Obstet Gynecol 1992; 167:653-60.
25. Hillis SD, Joesoef R, Marchbanks PA, Wasserheit JN, Cates W Jr, Weström L. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 1993; 168:1503-9.
26. Centers for Disease Control and Prevention. Pelvic inflammatory disease: guidelines for prevention and management. MMWR 1991; 40(RR-5):1-25.
27. Centers for Disease Control and Prevention. Recommendations for the prevention and management of Chlamydia trachomatis infections, 1993. MMWR 1993; 42(RR-12):1-39.
28. American Academy of Pediatrics, American College of Obstetrics and Gynecology. Guidelines for perinatal care. 3rd ed. Elk Grove Village, Ill: American Academy of Pediatrics, 1992.
29. US Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore, Md: Williams & Wilkins, 1996.